Subty** of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic
abnormalities, but recent literature indicates that transcriptomic phenoty** holds immense …

Despite some encouraging successes, predicting the therapy response of acute myeloid
leukemia (AML) patients remains highly challenging due to tumor heterogeneity. Here we …

Background Whole-genome sequencing (WGS) and whole-transcriptome sequencing
(WTS), with the ability to provide comprehensive genomic information, have become the …

Numerous studies have been performed over the last decade to exploit the complexity of
genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML) …

Acute myeloid leukemia (AML) is a highly heterogeneous malignant disease of the blood
cell. The current therapies for AML are unsatisfactory and the molecular mechanisms …

Breast cancer is a heterogeneous disease caused by various alterations in the genome or
transcriptome. Molecular subtypes of breast cancer have been reported, but useful …

Diacylglycerol kinases (DGKs) play dual roles in cell transformation and
immunosurveillance. According to cancer expression databases, acute myeloid leukemia …

The expression abundance of transcripts in nondiseased breast tissue varies among
individuals. The association study of genotypes and imaging phenotypes may help us to …

Subty** of acute myeloid leukaemia (AML) has made significant progress, exemplified by
the recent classification updates by the World Health Organization and International …

The human body is made of trillions of cells that are the building blocks of all living things.
Hematopoietic cells are a set of such building blocks. They are made in the bone marrow …